262 related articles for article (PubMed ID: 35742901)
41. Ceritinib is a novel triple negative breast cancer therapeutic agent.
Dong S; Yousefi H; Savage IV; Okpechi SC; Wright MK; Matossian MD; Collins-Burow BM; Burow ME; Alahari SK
Mol Cancer; 2022 Jun; 21(1):138. PubMed ID: 35768871
[TBL] [Abstract][Full Text] [Related]
42. Combined bazedoxifene and paclitaxel treatments inhibit cell viability, cell migration, colony formation, and tumor growth and induce apoptosis in breast cancer.
Fu S; Chen X; Lo HW; Lin J
Cancer Lett; 2019 Apr; 448():11-19. PubMed ID: 30707920
[TBL] [Abstract][Full Text] [Related]
43. Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
Arango NP; Yuca E; Zhao M; Evans KW; Scott S; Kim C; Gonzalez-Angulo AM; Janku F; Ueno NT; Tripathy D; Akcakanat A; Naing A; Meric-Bernstam F
Breast Cancer Res; 2017 Aug; 19(1):93. PubMed ID: 28810913
[TBL] [Abstract][Full Text] [Related]
44. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
45. Targeting of apoptotic pathways by SMAC or BH3 mimetics distinctly sensitizes paclitaxel-resistant triple negative breast cancer cells.
Panayotopoulou EG; Müller AK; Börries M; Busch H; Hu G; Lev S
Oncotarget; 2017 Jul; 8(28):45088-45104. PubMed ID: 28187446
[TBL] [Abstract][Full Text] [Related]
46. The combined effect and mechanism of antiangiogenic drugs and PD-L1 inhibitor on cell apoptosis in triple negative breast cancer.
Li J; Zhang D; Liu Z; Wang Y; Li X; Wang Z; Liang G; Yuan X; Li Y; Komorowski AL; Rozen WM; Orlandi A; Takabe K; Franceschini G; Jerusalem G; Wang X
Ann Transl Med; 2023 Jan; 11(2):83. PubMed ID: 36819490
[TBL] [Abstract][Full Text] [Related]
47. SH003 selectively induces p73‑dependent apoptosis in triple‑negative breast cancer cells.
Choi EK; Kim SM; Hong SW; Moon JH; Shin JS; Kim JH; Hwang IY; Jung SA; Lee DH; Lee EY; Lee S; Kim H; Kim D; Kim YS; Choi YK; Kim HI; Choi HS; Cho SG; Kim JE; Kim KP; Hong YS; Lee WK; Lee JS; Kim TW; Ko SG; Jin DH
Mol Med Rep; 2016 Oct; 14(4):3955-60. PubMed ID: 27599791
[TBL] [Abstract][Full Text] [Related]
48. The sirtuin inhibitor cambinol impairs MAPK signaling, inhibits inflammatory and innate immune responses and protects from septic shock.
Lugrin J; Ciarlo E; Santos A; Grandmaison G; dos Santos I; Le Roy D; Roger T
Biochim Biophys Acta; 2013 Jun; 1833(6):1498-510. PubMed ID: 23499872
[TBL] [Abstract][Full Text] [Related]
49. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
50. ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non-Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms.
Ralff MD; Kline CLB; Küçükkase OC; Wagner J; Lim B; Dicker DT; Prabhu VV; Oster W; El-Deiry WS
Mol Cancer Ther; 2017 Jul; 16(7):1290-1298. PubMed ID: 28424227
[TBL] [Abstract][Full Text] [Related]
51. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
[TBL] [Abstract][Full Text] [Related]
52. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells.
Huang O; Zhang W; Zhi Q; Xue X; Liu H; Shen D; Geng M; Xie Z; Jiang M
Exp Biol Med (Maywood); 2015 Apr; 240(4):426-37. PubMed ID: 25304315
[TBL] [Abstract][Full Text] [Related]
53. An in vitro study on the reversal of epithelial to mesenchymal transition by brusatol and its synergistic properties in triple-negative breast cancer cells.
Chandrasekaran J; Balasubramaniam J; Sellamuthu A; Ravi A
J Pharm Pharmacol; 2021 Apr; 73(6):749-757. PubMed ID: 33769483
[TBL] [Abstract][Full Text] [Related]
54. Structure-based identification of novel sirtuin inhibitors against triple negative breast cancer: An in silico and in vitro study.
Sinha S; Patel S; Athar M; Vora J; Chhabria MT; Jha PC; Shrivastava N
Int J Biol Macromol; 2019 Nov; 140():454-468. PubMed ID: 31404596
[TBL] [Abstract][Full Text] [Related]
55. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
56. Expression and regulatory function of miRNA-182 in triple-negative breast cancer cells through its targeting of profilin 1.
Liu H; Wang Y; Li X; Zhang YJ; Li J; Zheng YQ; Liu M; Song X; Li XR
Tumour Biol; 2013 Jun; 34(3):1713-22. PubMed ID: 23430586
[TBL] [Abstract][Full Text] [Related]
57. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
58. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
[TBL] [Abstract][Full Text] [Related]
59. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer.
Demeule M; Charfi C; Currie JC; Larocque A; Zgheib A; Kozelko S; Béliveau R; Marsolais C; Annabi B
Cancer Sci; 2021 Oct; 112(10):4317-4334. PubMed ID: 34314556
[TBL] [Abstract][Full Text] [Related]
60. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
